Stock Analysis
MetLife, Inc. (MET) Stock Analysis
MetLife, Inc. (MET) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
MetLife, Inc. (MET) currently has an AIQ Score of 62/100, indicating a neutral setup. Risk is the strongest factor at 78/100. Quality is the weakest current factor at 43/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MET at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $97.14 |
| AIQ Score | 62/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $60.75B |
| P/E Ratio | 9.66 |
| Forward P/E | — |
| EPS | $1.10 |
| Revenue TTM | $18.88B |
| Dividend Yield | 0.01% |
| Beta | 0.76 |
| Volume | 2.63M |
| 52-week range | $67.33-$100.93 |
| RSI 14 | 60.26 |
| 50-Day SMA | $94.96 |
| 200-Day SMA | $82.27 |
| Analyst Price Target | $98.12 |
| Next Earnings | Nov 4, 2026 |
MET
OverviewMET Stock Analysis Summary
MetLife, Inc. (MET) currently has an AIQ Score of 62/100, indicating a neutral setup. Risk resilience is the strongest factor at 78/100. Quality is the weakest current factor at 43/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MET has AIQ Score of 62/100 with Risk resilience base of 78/100 and fading Quality at 43/100. Wait for component alignment before adding exposure.
Risk resilience (78/100) leads while Quality (43/100) lags. This cross-factor spread creates entry timing uncertainty.
Financial Services · 0.37% stock move · MET classified in Insurance - Life.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MET Bullish or Bearish Right Now?
MET currently has a neutral overall setup. Risk Resilience is the strongest factor at 78/100, while Quality is weakest at 43/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 70/100.
- - Risk Resilience is supportive at 78/100.
- - Price is +2.29% above its 50-day SMA.
- - Analyst target implies +1.01% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (29 vs 9).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
MET's Technical Analysis Consensus is currently Buy, with 29 buy, 7 neutral, and 9 sell votes. MET's 14-day RSI is 60.26, which places the stock in a constructive momentum range. MET's beta is 0.76, indicating lower market sensitivity than the broad market.
What Changed in MET?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the MET Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MET Decision Framework
Public evidence layers, setup checks, and risk context for MetLife, Inc..
MetLife, Inc. (MET) Stock Analysis
MetLife, Inc. has an AIQ Score of 62/100 in a Neutral regime. Risk is strongest at 78/100. Beta is 0.76, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MET is in a Neutral AIQ regime with score 62/100. |
| Signal Conflict | The primary conflict is that risk leads at 78/100 while quality lags at 43/100. |
| Factor Evidence | Momentum 70/100 · Value 66/100 · Quality 43/100 · Risk 78/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 78/100.
Momentum is 70/100 and RSI (14) is 60.3.
MET is in a Neutral regime at 62/100.
Risk factor is 78/100 with beta 0.76 and annual volatility 23.8%.
Current conflict: risk leads at 78/100 while quality lags at 43/100.
MET Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MET Fundamentals
MET valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MET Technical Analysis
MET technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MET Stock Catalysts
Track MET earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MET Dividend Analysis
MET dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MET Financial Data
MET revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MET Risk Analysis
MET volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MET Stock News
MET stock news, market tone, recent headlines, and catalyst context.
MET vs Insurance Peers
Current peer cohort: MET · MFC · PGR · PRU · TRV. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MET Current stock | 62/100 | 66/100 | 70/100 | 78/100 | 0.8 | 23.80% | Current |
| MFC Manulife Financial | 62/100 | 56/100 | 68/100 | 78/100 | 1.61 | 20.22% | MET vs MFC |
| PGR Progressive | 57/100 | 59/100 | 41/100 | 46/100 | -0.44 | 27.33% | MET vs PGR |
| PRU Prudential Financial | 56/100 | 70/100 | 43/100 | 73/100 | 0.45 | 22.81% | MET vs PRU |
| TRV Travelers Companies | 63/100 | 63/100 | 62/100 | 55/100 | 1.34 | 20.88% | MET vs TRV |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 10, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts7 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MET
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MET
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MET Stock FAQ
What is MET stock price today?
MetLife, Inc.'s current stock price is $97.14. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MET bullish or bearish right now?
MET's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MET's market cap?
MET's market cap is $60.75B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MET's current P/E ratio?
MET's current P/E ratio is 9.66 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MET's RSI?
MET's 14-day RSI is 60.26 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MET above its 50-day and 200-day moving averages?
MET is 2.29% from its 50-day SMA and 18.07% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MET's next earnings date?
MET's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MET pay a dividend?
MET's dividend yield is 0.01% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.